Buffett Critiques a 66% Healthcare Portfolio: The Cost of Speculation

Well, hello there. I was just pouring myself a Cherry Coke and looking over your "Global Life Sciences Alpha Fund." That sounds exactly like the kind of fancy name the Wall Street boys use to charge a "two and twenty" fee structure! Charlie Munger used to say that if you want to understand biology, study biology, but if you want to understand investing, study human nature. Looking at this portfolio, it seems you’re trying to do both, and you might just end up with a nasty case of financial indigestion.

You’ve built a portfolio that looks less like a diversified investment vehicle and more like my doctor's prescription pad. Now, I’ve got nothing against medicine—it's kept me ticking all these years—but betting your entire financial future on FDA approvals and clinical trials is a mighty bold move. Let’s sit down, pull up a chair, and look at the businesses you actually own here.

When I look at your sector breakdown, I don't see a portfolio; I see a hospital wing. You've got nearly 66% sitting directly in healthcare stocks, another 15% wrapped up in a healthcare ETF (XLV), and 15% in a private biotech firm. You are essentially all-in on one industry. We like to stick to our circle of competence at Berkshire, so if you happen to be a world-renowned geneticist, maybe this makes sense. Otherwise, as I've said, diversification is protection against ignorance.

Let's look at the actual businesses. You’ve got almost a quarter of your money tied up in Eli Lilly (12.4%) and Novo Nordisk (11.8%). These are wonderful businesses with tremendous intangible assets—specifically, those weight-loss drug patents that everyone and their neighbor is talking about. But remember, a wonderful business can be a terrible investment if you overpay for it. You’ve got nearly 47% of your strategy tilted toward aggressive growth, which usually means paying nosebleed prices for future earnings that might never materialize.

I do see some things I like. UnitedHealth (9.3%) is a beautiful business with a massive scale advantage. Intuitive Surgical (8.1%) and Stryker (5.5%) benefit from high switching costs—once a hospital trains its surgeons on a million-dollar robot, they aren't going to swap it out for a competitor's machine just to save a few pennies. That’s a real competitive moat.

But then there's your cash. At just 4.3%, your cash reserves are running on fumes. Now, I always say idle cash is dead capital, but having less than 5% means you have absolutely no dry powder. When Mr. Market gets depressed and puts wonderful businesses on sale, you won't have a dime to take advantage of it. You're walking into a storm without an umbrella.

🚩 Venture Capital Cosplay: You've got 15.2% of your portfolio sitting in a pre-IPO Biotech Startup. This isn't investing; it's pure speculation. This business has no moat, no public track record, and a high probability of going to zero if clinical trials fail. You don't need to bet the farm on unproven ideas to get rich.

🚩 Patent Cliffs and Margin of Safety: Over 42% of your portfolio's competitive advantage relies on intangible assets—mainly patents. Drug patents expire. When they do, the moat vanishes overnight and generic competition floods in. Paying sky-high prices for LLY and NOVO today gives you absolutely no margin of safety if the GLP-1 market gets crowded.

🚩 Extreme Sector Concentration: Being entirely exposed to North American and European healthcare means your net worth is entirely at the mercy of government regulations, Medicare pricing negotiations, and the FDA. That is an enormous blind spot.

🚩 Holding Onto Yesterday's Lottery Tickets: Moderna at 4.2%. It was a miracle during the pandemic, but the world has moved on. Chasing past momentum usually leaves you holding the bag.

I'm giving this portfolio a 4 out of 10. You own some truly spectacular businesses, but your portfolio construction is dangerously concentrated, and your risk profile is out of whack.

Here is what I would do if I were in your shoes:

1. Build Your Cash Reserves: Trim some of your winners—particularly the high-flying weight-loss drug makers where growth is priced to perfection—and get your cash position up to at least 10-15%. You need liquidity for when the market eventually panics.

2. Step Out of the Hospital: Start looking for wonderful businesses outside of healthcare. Find companies in consumer goods, financials, or industrials where the business model doesn't require a decade of clinical trials to turn a profit.

3. Cap the Speculation: If you must gamble on pre-IPO startups, it shouldn't be 15% of your total pie. Limit speculative bets to money you are perfectly happy to lose entirely.

Remember what Charlie and I always say: "A wonderful company at a fair price beats a fair company at a wonderful price." You've found some wonderful companies, but I suspect you've paid wonderful prices for them. Keep your head down, demand a margin of safety, and don't let the Wall Street hype dictate your buy orders.